Eiger BioPharmaceuticals Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Out of Business

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Out of Business

Eiger BioPharmaceuticals General Information

Description

Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2155 Park Boulevard
  • Palo Alto, CA 94306
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2155 Park Boulevard
  • Palo Alto, CA 94306
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eiger BioPharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Out of Business 29-May-2025 Completed Out of Business
8. Bankruptcy: Admin/Reorg 01-Apr-2024 Completed Bankruptcy: Admin/Reorg
7. Secondary Transaction - Open Market Completed Generating Revenue
6. Secondary Transaction - Open Market Completed Generating Revenue
5. Reverse Merger 22-Mar-2016 Completed Generating Revenue
4. Later Stage VC Completed Generating Revenue
3. Later Stage VC 20-Nov-2015 Completed Generating Revenue
2. Later Stage VC (Series A1) 24-Mar-2015 $14.5M $22.8M Completed Generating Revenue
1. Early Stage VC (Series A) 17-Sep-2010 $8.3M $8.3M Completed Startup
To view Eiger BioPharmaceuticals’s complete valuation and funding history, request access »

Eiger BioPharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
Series A
To view Eiger BioPharmaceuticals’s complete cap table history, request access »

Eiger BioPharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercializ
Drug Discovery
Palo Alto, CA
25 As of 2023

Soborg, Denmark
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eiger BioPharmaceuticals Competitors (68)

One of Eiger BioPharmaceuticals’s 68 competitors is Zealand Pharma, a Formerly VC-backed company based in Soborg, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zealand Pharma Formerly VC-backed Soborg, Denmark
Capricor Therapeutics Formerly VC-backed San Diego, CA
BioAtla Formerly VC-backed San Diego, CA
Arbutus Biopharma Corporation Warminster, PA
Lisata Therapeutics Corporation Basking Ridge, NJ
You’re viewing 5 of 68 competitors. Get the full list »

Eiger BioPharmaceuticals Patents

Eiger BioPharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024123860-A1 Methods to treat hepatitis delta viral infections Inactive 07-Dec-2022
WO-2024123860-A9 Methods to treat hepatitis delta viral infections Inactive 07-Dec-2022
CA-3170254-A1 Treatment of coronavirus infection with interferon lambda Pending 16-Mar-2022
CA-3224859-A1 Treatment of congenital hyperinsulinism with avexitide Pending 21-Jun-2021
WO-2022271753-A1 Treatment of congenital hyperinsulinism with avexitide Inactive 21-Jun-2021 A61K38/26
To view Eiger BioPharmaceuticals’s complete patent history, request access »

Eiger BioPharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eiger BioPharmaceuticals Acquisitions (1)

Eiger BioPharmaceuticals’s most recent deal was a Merger/Acquisition with Celladon for . The deal was made on 22-Mar-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Celladon 22-Mar-2016 Merger/Acquisition Drug Discovery
To view Eiger BioPharmaceuticals’s complete acquisitions history, request access »

Eiger BioPharmaceuticals ESG

Risk Overview

Risk Rating

Updated December, 31, 2022

30.31 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,942

Rank

Percentile

Pharmaceuticals

Industry

of 914

Rank

Percentile

Biotechnology

Subindustry

of 412

Rank

Percentile

To view Eiger BioPharmaceuticals’s complete esg history, request access »

Eiger BioPharmaceuticals FAQs

  • When was Eiger BioPharmaceuticals founded?

    Eiger BioPharmaceuticals was founded in 2008.

  • Where is Eiger BioPharmaceuticals headquartered?

    Eiger BioPharmaceuticals is headquartered in Palo Alto, CA.

  • What is the size of Eiger BioPharmaceuticals?

    Eiger BioPharmaceuticals has 25 total employees.

  • What industry is Eiger BioPharmaceuticals in?

    Eiger BioPharmaceuticals’s primary industry is Drug Discovery.

  • Is Eiger BioPharmaceuticals a private or public company?

    Eiger BioPharmaceuticals is a Private company.

  • What is Eiger BioPharmaceuticals’s current revenue?

    The current revenue for Eiger BioPharmaceuticals is .

  • How much funding has Eiger BioPharmaceuticals raised over time?

    Eiger BioPharmaceuticals has raised $39.5M.

  • Who are Eiger BioPharmaceuticals’s competitors?

    Zealand Pharma, Capricor Therapeutics, BioAtla, Arbutus Biopharma, and Lisata Therapeutics are some of the 68 competitors of Eiger BioPharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process